Network meta-analysis

Percent body weight change

Type 2 diabetes (adults); background therapy: no glucose lowering drug (lifestyle only)

weeks 20 to 40 (target week 26)Treatment policyDoses of a drug pooledMean difference

Randomized trials

Treatments

782

Participants

Trial arms

In plain language

Across 2 trials with 782 participants, 0 of 2 treatments had a clearly better result than placebo on percent body weight change, and for 2 the evidence could not tell them apart from placebo. The most favorable estimate was for Safiglipron (HRS-7535) tablet: mean difference -2.10 percentage points (95% credible interval -8.98 to 4.83).

Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Effects compared with Placebo

Mean difference in percentage points. Lower values favor the treatment.

Versus Placebo. Blue: Bayesian random effects posterior median with 95% credible interval (thick) and 95% prediction interval (dashed). Amber diamond: frequentist estimate with 95% confidence interval. Hover over or tab to a row for its values.

Effects of each treatment versus Placebo
Treatment	Bayesian MD (95% CrI)	95% prediction interval	Frequentist MD (95% CI)	Verdict
Safiglipron (HRS-7535) tablet SAFIGL_PO	-2.10 (-8.98 to 4.83)	-12.12 to 8.01	-2.16 (-3.56 to -0.76)	Unclear
Semaglutide tablet SEMA_PO	-1.65 (-8.48 to 5.01)	-11.00 to 8.02	-1.67 (-2.36 to -0.97)	Unclear

Ranking

How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.

League table

Every treatment against every other: mean difference of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.

Every treatment in a row compared with every treatment in a column
Row versus column	PLACEBO	SAFIGL_PO	SEMA_PO
PLACEBO	PLACEBO	2.10 -4.83 to 8.98	1.65 -5.01 to 8.48
SAFIGL_PO	-2.10 -8.98 to 4.83	SAFIGL_PO	-0.43 -10.08 to 8.96
SEMA_PO	-1.65 -8.48 to 5.01	0.43 -8.96 to 10.08	SEMA_PO

Heterogeneity, fit and convergence

Bayesian random effects (primary)

Heterogeneity (tau): 2.243 (95% CrI 0.092 to 7.263)
Residual deviance: 4.1 for 4 data points
DIC: 8.1 (pD 4.1)
Largest R-hat: 1.002
Smallest ESS: bulk 2,264, tail 2,151
Divergent transitions: 0
Convergence: All criteria met
Priors: PR01 N(0, 35^2); PR03 N(0, 17.5^2); PR07 half normal(0, 3.5^2) on tau

Frequentist check (netmeta)

Method: inverse variance, REML, MD
Tau: 0.000
Q (total): 0.00 on 0 df
Q (between designs): 0.00

Inconsistency

Do trials comparing two treatments directly agree with the indirect evidence through other treatments?

No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting; the between designs Q above is the global check.

Small study effects

A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.

Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.

Baseline effect modifiers and prognostic factors per trial
Trial	Baseline BMI or body weight (kg/m2) effect modifier, prognostic factor; 2 of 2	Sex (percent female) effect modifier, prognostic factor; 2 of 2	Asian ancestry or region (percent Asian) effect modifier, prognostic factor; 2 of 2	Kidney function (eGFR) (mL/min/1.73 m2) prognostic factor, effect modifier; 1 of 2	Treatment duration (weeks) effect modifier; 2 of 2	Lifestyle co-intervention intensity (none standard intensive) effect modifier, prognostic factor; 2 of 2
OUTSTAND-1 S000213	27.83	33.09	100	not reported	52	not_reported
PIONEER 11 S001791	28.2	36.27	74.85	102.5	26	not_reported

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagBaseline, Kidney function (eGFR): not reported by 1 of 2 trials
FlagOutcome assessment, analysis set: confounded with design: full_analysis 1, randomized 1
FlagOutcome assessment, intercurrent events (discontinuation): confounded with design: hypothetical 1, treatment_policy 1
FlagOutcome assessment, intercurrent events (rescue): confounded with design: hypothetical 1, treatment_policy 1
NoteOutcome assessment, time point: selected time points span 26 to 32 weeks
NoteData handling, input conversions: arms_combined 2

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
OUTSTAND-1	32	randomized	not stated	not stated	not stated	not stated	treatment_policy	treatment_policy	double_blind	industry	2024	age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 19.0 to 40.0; diet and exercise only
PIONEER 11	26	full_analysis	not stated	not stated	not stated	not stated	hypothetical	hypothetical	double_blind	industry	2019	age 18 or older; HbA1c 7.0 to 10.0 percent at screening, 7.0 to 9.5 at randomization; no glucose lowering drugs; eGFR 60 or more

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the mean difference on the analysis scale against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Value	SE	Events / N	Flags	Source
OUTSTAND-1	A1+A2+A3	SAFIGL_PO	32	arm, percent_change	-3.380	0.369	212	arms_combined	R0011607:Table 2
OUTSTAND-1	A4	PLACEBO	32	arm, percent_change	-1.220	0.612	72		R0011607:Table 2
PIONEER 11	A1+A2+A3	SEMA_PO	26	arm, percent_change	-2.666	0.234	374	arms_combined	R0019663:Table 2
PIONEER 11	A4	PLACEBO	26	arm, percent_change	-1.000	0.269	124		R0019663:Table 2

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab